Chloroguanabenz . acetate
80 CHF CHF 80.00
AG-MR-C0036-M0011 mgCHF 80.00
AG-MR-C0036-M0055 mgCHF 320.00
|Synonyms||1-[(E)-2,3,6-Trichlorophenylmethyleneamino]guanidine; Hydrazinecarboximidamide, 2-[(2,3,6-trichlorophenyl)methylene]-; Guanabenz; Chlorine-Guanabenz|
C8H7Cl3N4 . C2H4O2
|MW||265.5 . 60.1|
|Purity Chemicals||≥95% (NMR)|
|Appearance||White to off-white powder.|
|Solubility||Soluble in DMSO or ethanol.|
|Reconstitution||Stock solutions can be made up to 10mM in DMSO.|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||After reconstitution, prepare aliquots and store at -20°C.|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- Antiprion agent.
- Inhibitor of protein aggregation.
- Specifically reduces accumulation of a pathogenic fragment of Huntingtin in a transiently transfected cellular model of Huntington’s disease (HD).
- Tool for treating HD and other polyglutamine expansion associated diseases.
- Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions: D. Tribouillard-Tanvier, et al.; PLoS One 3, e1981 (2008)
- Use of chlorine guanabenz derivatives for treating polyglutamine expansion associated diseases: A. Bertolotti & M. Blondel; Patent WO002008041133A2 (2008)
- Synthesis of conjugates of 6-aminophenanthridine and guanabenz, two structurally unrelated prion inhibitors, for the determination of their cellular targets by affinity chromatography: F. Gug, et al.; Bioconjug. Chem. 21, 279 (2010)